Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening

Status:	Active, not recruiting
Conditions:	Breast Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/3/2019
Start Date:	December 7, 2017
End Date:	December 2020

MSK Discovery Study: Use of cfNA To Distinguish Between Benign and Malignant BI-RADS 4 Radiographic Lesions

The purpose of this study is to collect blood and tissue to help develop tests that might be
able to detect cancer earlier. The investigator will be collecting these samples and
reviewing test results from participants who have had an area of concern found on breast
imaging, as well as from participants who are scheduled to have a routine breast cancer
screening mammogram.

Inclusion Criteria:

- Females with one or more BI-RADS 4 radiographic lesions who are undergoing ultrasound,
stereotactic or MRI-guided breast biopsy at MSKCC or at an MSK Alliance Member Site.
If multiple imaging modalities were employed (mammogram, ultrasound, MRI) and no
integrated score is provided, then the highest BI-RADS score will be used.

- Age ≥ 18 years at the time of breast biopsy

- Willing to provide blood samples for research purposes before biopsy.

- Able to provide written informed consent

Exclusion Criteria:

- Women with a BI-RADS 4 lesion who had the lesion previously biopsied

- Females with a current active malignancy other than non-melanoma skin cancers. Females
are considered not to have a "current active" malignancy if they have completed
therapy and have no evidence of systemic disease for at least three years from the
initial diagnosis

- Currently pregnant women

- History of bilateral mastectomy.

- Participant has or is currently participating in another GRAIL-sponsored protocol

We found this trial at

sites

Memoral Sloan Kettering Monmouth

480 Red Hill Road
Middletown, New Jersey 07748

Phone: 646-888-4510

from

Middletown, NJ